Inicio > Medicina Interna > Una nueva visión de la enfermedad pulmonar obstructiva crónica > Página 6

Una nueva visión de la enfermedad pulmonar obstructiva crónica

el pronóstico de estos enfermos.

Es de señalar el enorme valor de los biomarcadores para ciertos aspectos muy específicos de la enfermedad pulmonar obstructiva crónica (EPOC), como son; la susceptibilidad, progresión y aparición de complicaciones, donde pueden muy precozmente identificar y monitorear los aspectos clínicos de la enfermedad, su fenotipo y los mecanismos de protección y manejo. Al aumentar los estudios clínicos y moleculares, se reconoce cada vez más la necesidad de un grupo de biomarcadores para poder enfrentar la complejidad de esta entidad. Nosotros sugerimos un mayor acercamiento clínico a todo paciente mayor de 40 años con diagnóstico de asma bronquial, fumadores, con manifestaciones pulmonares, especialmente si son del sexo masculino para poder alcanzar un diagnóstico precoz de estos enfermos, y buscar con mucho esmero todas las co- morbilidades que lo puedan acompañar, valorando dentro de su estado clínico las inflamación sistémica y el uso de las estatinas.

Referencias bibliográficas

1.             Goh F, Shaw JG,Savarimuthu Francis S M,Vaughan A, Morrison L, Relan V, et al. Personalizing and Targeting Therapy for COPD and The Role of Molecular and Clinical Biomarkers. Expert Rev Resp Med. 2013;7(6):593-605

  1. Vestbo J, Hurd SS, Agustí AG. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. J. Respir. Crit. Care Med 2013; 187(4), 347–65
  2. Lozano R, Naghavi M, Foreman K. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380(9859), 2095–128
  3. Zeng G, Sun B, Zhong N. Non-smoking-related chronic obstructive pulmonary disease: a neglected entity? Respirology 2012; 17(6), 908–12
  4. Mathers CD, Loncar D: Updated projections of global mortality and burden of disease. [Internet], 2002–2030: data sources, methods and results.[Último acceso 20 febrero 2014]. 2002–2030. Disponible en; http://www.who.int/healthinfo/statistics/bodprojectionspaper.pdf
  5. Siedlinski M, Tingley D, Lipman PJ. Dissecting direct and indirect genetic effects on chronic obstructive pulmonary disease (COPD) susceptibility. Genet 2013;132(4), 431–41
  6. Lindberg A, Larsson LG, Muellerova H, Rönmark E, Lundbäck B. Up-to-Date on Mortality in COPD. BMC Pulm Med. 2012;12(1) ; 1121- 31
  7. Halbert RJ, Isonaka S, George D, Iqbal A: Interpreting COPD prevalence estimates. What is the true burden of disease? Chest 2003; 123:1684–92.
  8. Lundbäck B, Lindberg A, Lindstrom M, Rönmark E, Jonsson AC, Jonsson E, et al. Not 15 but 50% of smokers develop COPD?–Report from the Obstructive Lung Disease in Northern Sweden Studies. Respir Med 2003; 97(2):115–22.
  9. Lindberg A, Bjerg A, Rönmark E, Larsson LG, Lundbäck B: Prevalence and underdiagnosis of COPD by disease severity and the attributable fraction of smoking Report from the Obstructive Lung Disease in Northern Sweden Studies. Respir Med 2006; 100(2):264–72.
  10. Jones R C. Price Ryan D. Sims EJ. Von Ziegenweidt J.  Mascarenhas L. et al. Opportunities to diagnose chronic obstructive pulmonary disease in routine care in the UK: a retrospective study of a clinical cohort. The Lancet Respiratory Medicine, [Internet] Early Online Publication, 13 February 2014 [Último acceso 20 febrero 2014 ]13 February 2014. doi:10.1016/S2213-2600(14)70008. Disponible en: http://www.thelancet.com/journals/lanres/article/PIIS2213-2600%2814%2970008-6.
  11. Decramer M, Janssens W, Miravitlles M. Chronic obstructive pulmonary disease. Lancet 2012; 379(9823), 1341–51.
  12. Lundbäck B, Eriksson B, Lindberg A, Ekerljung L, Muellerova H, Larsson L-G, Rönmark E: A 20-Year Follow-Up of a Population Study-Based COPD Cohort – Report from the Obstructive Lung Disease in Northern Sweden Studies. COPD: Journal of Chronic Obstructive Pulmonary Disease 2009; 6:263–71.
  13. Lindberg A, Lundbäck B: The OLIN COPD study. Design, the first year participation and mortality. Clin Respir J 2008; 2:64–71.
  14. Celli B, Decramer M, Kesten S, Liu D, Mehra S, Tashkin DP: UPLIFT study Investigators. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. AJRCCM 2009; 180(10):948–55.
  15. Mannino DM, Buist AS, Petty TL, Enright PL, Redd SC: Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up study. Thorax 2003; 58:388–93.
  16. Drummond MB, Hansel NN, Connett JE, Scanlon PD, Tashkin DP, Wise RA. Spirometric predictors of lung function decline and mortality in early chronic obstructive pulmonary disease. J. Respir. Crit. Care Med 2012; 185(12), 1301–6.
  17. Pedone C, Scarlata S, Sorino C, Forastiere F, Bellia V, Antonelli-Incalzi R: Does mild COPD affect prognosis in the elderly? Pulmonary Medicine [Internet]2010,[Último acceso 22 febrero 2014] 10:35 Disponible en: http://www.biomedcentral.com/1471–2466/10/35
  18. De Marco R, Accordini S, Anto J, Gislason T, Heinrich J, Janson C, Jarvis D, Kunzli N, et al. Long-term outcomes in mild/moderate chronic obstructive pulmonary disease in the European Community Respiratory Health Survey. AJRCCM 2009, 108:956–63.
  19. Montuschi P. Toward a personalized pharmacotherapy of respiratory diseases. Pharmacol 2010; 1; 131
  20. Montuschi P. Drugs for chronic obstructive pulmonary disease. Med. Chem.2013; 20(12), 1461–3.
  21. Bale G, Nartinez-Camblor P, Burge PS, Soriano JB: Long-term mortality follow-up of the ISOLDE participants: causes of death during 13 years after trial completion. Respir Med 2008; 102(10):1468–72.
  22. Rodríguez, E., Ferrer, J., Zock, J. P., Serra, I., Antó, J. M., de Batlle, J.et al.COPD Study Group. . Lifetime Occupational Exposure to Dusts, Gases and Fumes Is Associated with Bronchitis Symptoms and Higher Diffusion Capacity in COPD Patients. PloS one, 2014; 9(2), e88426.
  23. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. National Guideline Clearinghouse. [Internet] 2008. [Último acceso 21 febrero 2014] Disponible en: http://emedicine.medscape.com/article/807927-overview.
  24. Lamprecht B, McBurnie MA, Vollmer WM, Gudmundsson G, Welte T, Nizankowska-Mogilnicka E, et al. COPD in Never Smokers: Results From the Population-Based Burden of Obstructive Lung Disease Study. Chest. Apr 2011;139(4):752-63.
  25. Montuschi P. Pharmacological treatment of chronic obstructive pulmonary disease. J. Chron. Obstruct. Pulmon. Dis 2006; 1(4), 409–23 (2006).